超免疫血清疗效低的原因之一在于抗体的亲合力之不同一性,因而在上述制剂中高亲合力抗体只占很小部分,而亲合力低的抗体则占大部分。下一代免疫球蛋白制剂的生物技术(即生物工程——译者注)应该植根于从超免疫血清和单克隆抗体中分离具有极高亲合力的 One of the reasons for the low efficacy of the hyperimmune serum is due to the different avidity of the antibodies, so high avidity antibodies account for only a small fraction of the above formulations, while the less avidity antibodies make up the majority. Biotechnology for next-generation immunoglobulin preparations should be rooted in the isolation of proteins that have a very high affinity for isolation from hyperimmune serum and monoclonal antibodies